PROMIS NEUROSCIENCES INC (PMN)

CA74346M4065 - Common Stock

1.26  +0.03 (+2.44%)

Fundamental Rating

0

Overall PMN gets a fundamental rating of 0 out of 10. We evaluated PMN against 573 industry peers in the Biotechnology industry. PMN may be in some trouble as it scores bad on both profitability and health. PMN has a expensive valuation and it also scores bad on growth.



Quickly go to:

0

1. Profitability

1.1 Basic Checks

PMN had negative earnings in the past year.
PMN had a negative operating cash flow in the past year.
PMN had negative earnings in each of the past 5 years.
PMN had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

PMN's Return On Assets of -865.44% is on the low side compared to the rest of the industry. PMN is outperformed by 99.12% of its industry peers.
Industry RankSector Rank
ROA -865.44%
ROE N/A
ROIC N/A
ROA(3y)-137.72%
ROA(5y)-229.81%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

PMN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

0

2. Health

2.1 Basic Checks

Compared to 1 year ago, PMN has more shares outstanding
PMN has more shares outstanding than it did 5 years ago.
There is no outstanding debt for PMN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

Based on the Altman-Z score of -28.00, we must say that PMN is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of PMN (-28.00) is worse than 89.96% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -28
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

A Current Ratio of 0.44 indicates that PMN may have some problems paying its short term obligations.
PMN's Current ratio of 0.44 is on the low side compared to the rest of the industry. PMN is outperformed by 94.72% of its industry peers.
PMN has a Quick Ratio of 0.44. This is a bad value and indicates that PMN is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of PMN (0.44) is worse than 94.01% of its industry peers.
Industry RankSector Rank
Current Ratio 0.44
Quick Ratio 0.44

More info and screens

0

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 72.77% over the past year.
EPS 1Y (TTM)72.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50.85%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to decrease by -7.20% on average over the next years.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y65.09%
EPS Next 2Y19.35%
EPS Next 3Y5.37%
EPS Next 5Y-7.2%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

PMN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year PMN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y19.35%
EPS Next 3Y5.37%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for PMN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PROMIS NEUROSCIENCES INC

NASDAQ:PMN (9/16/2024, 3:01:33 PM)

1.26

+0.03 (+2.44%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap23.89M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -865.44%
ROE N/A
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 0.44
Quick Ratio 0.44
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)72.77%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y65.09%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y